| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Internal Medicine and
Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
) and type II (IFN-
) IFNs have been heavily implicated in the pathogenesis of systemic lupus erythematosus. To test the relative roles of these systems, congenic lupus-prone MRL/CD95lpr/lpr (MRL/lpr) mice lacking the type I IFN receptor (IFN-RI), type II IFN receptor (IFN-RII), or both, were derived. As expected, deficiency for IFN-RII protected MRL/lpr mice from the development of significant autoimmune-associated lymphadenopathy, autoantibodies, and renal disease. However, deficiency for the IFN-RI surprisingly worsened lymphoproliferation, autoantibody production, and end organ disease; animals doubly deficient for IFN-RI and IFN-RII developed an autoimmune phenotype intermediate between wild-type and IFN-RII-deficient animals, all correlating with an ability of type I IFN to suppress MRL B cell activation. Thus, type I IFNs protect against both the humoral and end organ autoimmune syndrome of MRL/lpr mice, independent of IFN-. These findings warrant caution in the use of type I IFN antagonists in the treatment of autoimmune diseases and suggest further investigation into the interplay between the types I and II IFNs during the ontogeny of pathogenic autoantibodies. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
often adversely induces autoimmunity, particularly autoantibody production by B cells (7); 3) both types I and II IFNs can promote class switch recombination to Th1-like IgG isotypes (IgG2a, IgG2b, IgG3), pathogenic, complement-fixing isotypes in lupus (8, 9, 10, 11); 4) inappropriate expression of the IFNs appears to be capable of breaking tolerance and/or at least augmenting humoral autoimmunity, in part via the activation of dendritic cells (12); and 5) multiple murine lupus studies, involving genetically altered and/or therapeutically manipulated animals, have demonstrated the clear importance of the type II IFNs to autoantibody production and subsequent organ damage (13, 14, 15, 16, 17, 18, 19). In addition, one recent study has demonstrated that deficiency in IFNAR1, the gene encoding the subunit of the heterodimeric IFN-I receptor, protected from anti-erythrocyte autoantibodies, hemolytic anemia, anti-DNA Abs, kidney disease, and mortality in the New Zealand Black (NZB) model of autoimmune hemolytic anemia and immunocommplex glomerulonephritis (20). Similarly, IFNAR1 deficiency protected lpr mice of a mixed 129 x C57BL/6 background from lymphadenopathy and renal immune complex deposition, and sustained administration of the IFN-I inducer polyinosinic:polycytidylic acid to C57BL/6-lpr mice aggravated autoantibodies, hypergammaglobulinemia, lymphocyte activation, and renal disease (21). Thus, the IFNs have emerged as a dominant target in the pathogenesis of SLE.
The type I and type II IFN systems significantly interact with each other during immune responses, sometimes bolstering and/or attenuating the effect of the other, such as the promotion (22) vs inhibition (23) of IFN--producing Th1 and/or dendritic cells by type I IFNs (4, 24, 25). As such, type I IFNs may contribute to SLE by promoting and/or augmenting the production of IFN-, as opposed to playing a direct pathogenic role in the promotion of autoantibody production. Indeed, the only definitively demonstrated pathogenic target of the IFNs in humoral autoimmunity, the T-box transcription factor T-bet, is an IFN--, but not type I IFN-, induced gene (11, 26), suggesting that perhaps the role of the type I IFNs is adjunctive to IFN-. At the same time, several other type I and type II IFN-induced or -related genes, such as Ifi202, have been implicated in genetic and animal studies, at least in the NZB background (20, 27); therefore, the direct importance of the type I IFNs remains an open question.
Such considerations raise the possibility that the IFNs may play different roles in different SLE subtypes. Indeed, the previously published studies on murine lupus in the setting of IFN-RI deficiency have used autoimmune-prone backgrounds of relatively low-to-moderate severity, NZB (20) and a mixed 129 x C57BL/6-lpr (21). The former develops moderate autoimmune hemolytic anemia as well as chronic Ig deposition in the kidney related to anti-DNA Abs; however, only the F1 NZB x NZW hybrids develop severe, lethal crescentic glomerulonephritis related to high titer, high affinity anti-dsDNA Abs (28). Similarly, without the MRL genetic background, the lpr mutation induces only a mild anti-DNA response and renal Ig depostion (28, 29). Thus, it remains unclear whether or not type I IFNs are also pathogenic in severe lupus, as might be characterized by multisystem disease and/or high titer, high affinity autoantibodies of multiple specificities.
Of the known inbred lupus-prone mouse strains, MRL/lpr develops the most intense syndrome that resembles severe human human disease, developing multisystem inflammation, including severe, crescentic glomerulonephritis, and a similar spectrum of autoantibodies including anti-dsDNA and anti-small nuclear RNP (28, 30). We therefore sought to determine directly the relative contributions of the type I and II IFNs in this model and generated congenic MRL/lpr animals deficient in IFN-RI and/or IFN-RII. Surprisingly, IFN-RI-deficient animals developed worsened serological, cellular, and histological parameters of autoimmunity, in contrast to IFN-RII-deficient animals, which were largely protected from disease. Thus, at least in this model of humoral autoimmune disease, the type I IFNs suppress autoimmunity. Further studies of the pathogenesis and therapy of murine lupus should exercise caution with respect to the divergent roles of the type I and II IFNs.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
BALB/cJ, MRL/MpJ (MRL/+) and MRL/MpJ-CD95lpr/lpr (MRL/lpr) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). IFN-RI (IFNAR1, CD118)–/– IFN-RII (IFNGR, CD119)–/– doubly deficient mice of the 129 background (AG129; Refs. 31 and 32) were graciously provided to us by Drs. H. Virgin and W. Yokoyama (Washington University School of Medicine, St. Louis, MO). To derive lupus-prone mice deficient in the type I and/or type II IFN receptors, the IFN-RI- and RII null alleles from AG129 mice were continually backcrossed at least six times against the MRL/lpr background until all 24 known MRL disease susceptibility loci (Refs. 33, 34, 35, 36 and our unpublished data), as well as H-2 (k/k; Ref, 37) and CD95 (38), had been bred to MRL homozygosity using STS marker-assisted genotyping. Then, IFN-RI+/– IFN-RII+/– MRL/lpr animals were crossed against MRL/+ animals to generate IFN-RI+/– IFN-RII+/– MRL-CD95+/lpr animals, which were intercrossed to generate IFN-RI+/+ or IFN-RI–/–, IFN-RII+/+ or IFN-RII–/–, CD95+/+ or lpr/lpr animals for use in this study. All experiments were performed in compliance with the relevant laws and institutional guidelines, as overseen by the Animal Studies Committee of the Washington University School of Medicine.
Murine lupus assessment
Assessments for autoimmunity were performed essentially as described (30, 39). Briefly, sera were assessed for total Ig isotypes by standard ELISA (Southern Biotechnology Associates, Birmingham, AL). IgG anti-DNA activity was determined by ELISA on sera at 1/100 dilution using calf thymus DNA (Sigma-Aldrich, St. Louis, MO). Total 
-chain rheumatoid factor activity was determined by ELISA on sera at 1/100 dilution using pooled 
-chain IgG1, IgG2a, IgG2b, and IgG3 Abs for capture, followed by alkaline phosphatase anti-mouse Ig for detection (BD PharMingen, San Diego, CA). Proteinuria was determined on collected urine by the DC protein assay kit (Bio-Rad Laboratories, Hercules, CA).
Histopathology was evaluated on paraffin-embedded, formalin-fixed tissue sections by routine H&E staining. IgG immune deposits were determined by direct immunofluorescence on 5 µM OCT-embedded frozen kidney sections, using FITC anti-mouse IgG (Pierce Biotechnology, Rockford, IL). Histopathological assessments were determined in blinded fashion by one of us (S.L.P.).
Flow cytometry
Flow cytometric analyses were performed on a FACSCalibur System (BD Biosciences, San Jose, CA) using lymph node cells and/or splenocytes cleared of RBC by osmotic lysis. Abs used included FITC-145-2C11 (anti-CD3), PE-53-6.7 (anti-CD8), APC-RA3-6B2 (anti-CD45R/B220), and PE-Cy7-RM4-4 (anti-CD4; BD PharMingen).
In vitro B cell assays
Naive splenic B cells were purified by negative selection against CD43 and cultured in RPMI medium supplemented with LPS, 25 µg/ml (Sigma-Aldrich); anti-CD40, 2 µg/ml (BD PharMingen); IL-12, 1 ng/ml; IL-18, 2.5 ng/ml, and/or IFN-, 100 ng/ml (PeproTech, Rocky Hill, NJ), as described (40). Universal type I IFN (IFN-A/D), which activates the murine type I IFN receptor, was supplemented at 100–10,000 U/ml as indicated in the text (R&D Systems, Minneapolis, MN). At the times indicated, Ig and cytokine secretion was assayed in culture supernatants by ELISA, and cell proliferation was determined by BrdU incorporation, as described (40, 41).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To determine the relative roles of the types I and II IFNs in MRL/lpr lupus, congenic MRL animals of the IFN-RI+/–IFN-RII+/–CD95+/lpr genotypes were intercrossed to generate IFN-RI+/+ or IFN-RI–/–, IFN-RII+/+ or IFN-RII–/–, CD95+/+, or lpr/lpr animals. For consistency with prior nomenclature (32, 42), the 8 genotypes produced are referred herein as MRL/+ (IFN-RI+/+IFN-RII+/+CD95+/+), AMRL/+ (IFN-RI–/–IFN-RII+/+CD95+/+), GMRL/+ (IFN-RI+/+IFN-RII–/–CD95+/+), AGMRL/+ (IFN-RI–/–IFN-RII–/– CD95+/+), MRL/lpr (IFN-RI+/+IFN-RII+/+ CD95lpr/lpr), AMRL/lpr (IFN-RI–/–IFN-RII+/+CD95lpr/lpr), GMRL/lpr (IFN-RI+/+IFN-RII–/–CD95lpr/lpr), and AGMRL/lpr (IFN-RI–/–IFN-RII–/–CD95lpr/lpr). All genotypes were generated at expected Mendelian ratios.
A suppressive role for the IFN-I receptor in the autoimmune hypergammaglobulinemia of MRL/lpr mice
Disease parameters were first assessed in 12-wk-old animals, when the penetrance of both humoral autoimmunity and end organ disease in MRL/lpr mice has reached 90–100% (28). Total serum Ig analysis (Fig. 1) demonstrated that MRL/lpr animals developed an expected hypergammaglobulinemia of all isotypes examined, as compared with their MRL/+ counterparts (p < 0.0001 for all isotypes). GMRL/lpr animals developed substantially lower serum titers of the pathogenic isotypes IgG2a, IgG2b, and IgG3, as well as IgM and IgA, but higher titers of IgG1 (p < 0.0001 for all indicated comparisons, MRL/lpr vs GMRL/lpr). Interestingly, pathogenic IgG titers in GMRL/lpr mice were not always reduced to normal levels: although their titers of IgG2a and IgG3 were comparable with those of MRL/+ animals (p not significant, comparing MRL/+ with GMRL/lpr), GMRL/lpr mice developed clearly elevated IgG2b titers (p < 0.0001, comparing MRL/+ with GMRL/lpr); nonetheless, these titers were substantially elevated compared with nonautoimmune C57BL/6 or BALB/c mice, which spontaneously produce serum IgG1, IgG2aa or b, IgG2b, and IgG3 in titers <100–200 µg/ml (p < 0.0001 for all isotypes, compared with GMRL/lpr; Ref. 43 and data not shown). These findings persisted in older animals examined at 24 wk of age (Fig. 2; p < 0.0001 for all aforementioned comparisons). Thus, reminiscent of prior studies (13, 14, 15), type II IFN was critically required for the full blown development of hypergammaglobulinemia of the Th1-like isotypes IgG2a, IgG2b, and IgG3 in MRL/lpr mice, although some degree of elevated Ig, presumably autoimmune-related, persisted.
|
|
activity; they suppress autoimmune hypergammaglobulinemia in the presence of IFN-RII but instead promote hypergammaglobulinemia in the absence of IFN-RII. Still, for all pathogenic isotypes (IgG2a, IgG2b, and IgG3), AGMRL/lpr animals developed significantly lower titers than their AMRL/lpr counterparts (p < 0.0001), indicating that whatever the specific effect of type I IFNs, IFN- contributed a substantial pathogenic role to autoimmune hypergammaglobulinemia. Expression of a type I IFN receptor suppresses humoral autoimmunity in MRL/lpr mice, independently of IFN-II
As expected, MRL/lpr mice developed significantly elevated serum activities of anti-DNA and -chain rheumatoid factor (RF) autoantibodies, compared with their MRL/+ counterparts (Fig. 3; p < 0.0001). As also expected, GMRL/lpr animals developed significantly lower serum activities of both anti-DNA (p < 0.0001) and RF (p < 0.001) Abs than MRL/lpr mice, although the effect on the latter was less pronounced. Indeed, the ELISA-positive anti-DNA Abs of GMRL/lpr animals were likely anti-ssDNA, rather than anti-dsDNA, in specificity: whereas 7 of 10 and 5 of 5 MRL/lpr sera at 12 and 24 wk of age, respectively, reacted with the dsDNA-containing kinetoplast of Crithidia luciliae substrates, 0 of 12 and 0 of 5 GMRL/lpr sera at 12 and 24 wk of age, respectively, did (Fig. 2; p < 0.00001). Analogous findings were seen in MRL/+ vs GMRL/+ sera, with 2 of 8 MRL/+ sera developing Crithidia-positive anti-dsDNA activity by 24 wk of age, in contrast to 0 of 10 GMRL/+ (p < 0.01). GMRL/+ also produced significantly, albeit modestly, lower titers of RF compared with their MRL/+ counterparts (p < 0.01 for 12 wk, p < 0.10 for 24 wk). Thus, type II IFN was critically required for the development of humoral autoimmunity, as evidenced by effects of IFN-RII deficiency on both anti-DNA and RF autoantibodies.
|
. At 12 wk of age, 7 of 7 (100%) of AMRL/lpr sera were Crithidia positive, in contrast to the 7 of 10 (70%) MRL/lpr (p < 0.05); and by 24 wk, 7 of 13 (54%) of AGMRL/lpr sera were Crithidia positive, in contrast to 0 of 5 GMRL/lpr sera (p < 0.0001). Similar findings were seen with MRL/+ sera, where by 24 wk 2 of 8 (25%) were Crithidia positive, in contrast to 5 of 8 (63%) AMRL/+, 0 of 10 (0%) GMRL/+, and 4 of 12 (33%) AGMRL/+ sera (p < 0.001 comparing MRL/+ with AMRL/+ or GMRL/+ with AGMRL/+). Interestingly, IFN-RI deficiency had a variable effect on RF activity, with higher titers in AMRL/+ animals than their MRL/+ counterparts, and higher titers in AMRL/lpr animals than their MRL/lpr counterparts at 24 wk (p < 0.01), but seemingly lower titers in AGMRL/lpr animals compared with their GMRL/lpr counterparts at 24 wk (p < 0.10). Nonetheless, these results strongly suggest that type I IFNs play a critical role in antagonizing the development of pathogenic humoral autoimmunity in MRL mice. Suppressive vs pathogenic roles for IFN-I and IFN-II receptors in lpr-related lymphoproliferation
Similarly, examination of lpr-related lymphoproliferation revealed divergent roles for the type I and II IFNs (Table I). MRL/lpr mice developed massive lymphadenopathy, with peripheral lymph node weights of typically 
1.2–1.6 g, composed largely of CD3+CD4–CD8–B220+ T cells at the expense of normal CD4+B220– and CD8+B220– T cells (p < 0.00001 comparing MRL/lpr to MRL/+, which typically yielded lymph node weights of 20–40 mg with CD4+B220– and CD8+B220– percentages of 20–25%). This lymphoaccumulation was greatly reduced in GMRL/lpr mice, which developed significantly lower lymph node weights (0.1–0.3 g) in association with lower percentages of CD3+CD4–CD8–B220+ T cells (15–20%) and more normal percentages of CD4+B220– and CD8+B220– cells (10–12%; p < 0.001 comparing weights and indicated percentages between MRL/lpr and GMRL/lpr mice). Thus, IFN-II plays a critical role in the development of lpr-related lymphoaccumulation.
|
Suppressive vs pathogenic roles for IFN-I and IFN-II receptors in MRL end organ disease
MRL/lpr animals developed severe end organ inflammation of the salivary gland, liver, lung, and kidney, all of which were largely absent in MRL/+, AMRL/+, GMRL/+, and AGMRL/+ animals (p < 0.0001; Fig. 4 and Table II). Renal disease was characterized by membranoproliferative glomerulonephritis, as well as glomerular and often tubular and tubular intracellular immune deposits (Figs. 4–6 and Table II). GMRL/lpr animals were largely protected from all end organ manifestations: at 12 wk of age, none of the animals developed detectable infiltrates of the salivary glands, liver or lung; and their renal disease was reduced in terms of inflammatory infiltrates, glomerular proliferation, and immune deposits, although mild renal disease was seen in older animals (Table II). Therefore, IFN-RII played a critical role in the development of autoimmune end organ disease in MRL/lpr animals.
|
|
|
|
Similarly, AGMRL/lpr animals in general developed worsened end organ disease compared with their GMRL/lpr counterparts (Fig. 4), developing mild-to-moderate infiltrates of the salivary gland, liver, and lung, all of which were largely absent in GMRL/lpr animals (p < 0.0001). Interestingly, AGMRL/lpr animals developed worsened renal disease in comparison with GMRL/lpr counterparts, accumulating significant immune deposits as well as overt glomerular hypercellularity (Figs. 4–6 and Table II; p < 0.001). In addition, whereas only minimal, if any, perivascular lesions were seen in GMRL/lpr kidneys, AGMRL/lpr kidneys consistently developed mild-to-moderate perivascular lesions (Fig. 4 and Table II) that were clearly distinguishable from GMRL/lpr specimens, although they did not reach the intensity of MRL/lpr or AMRL/lpr animals.
In accordance with all these findings, IFN-RII deficiency protected MRL animals from proteinuria (100% of MRL/lpr vs 13% of GMRL/lpr animals at 24 wk developed proteinuria >30 mg/ml; p < 0.0001; Table II, which shows only animals examined histopathologically, and data not shown), but IFN-RI deficiency significantly worsened proteinuria (at 24 wk, 58% of MRL/lpr vs 100% of AMRL/lpr animals developed proteinuria >100 mg/ml; 0% of GMRL/lpr vs 44% of AGMRL/lpr animals developed proteinuria >30 mg/ml; p < 0.0001 for both comparisons; Table II and data not shown; n = 10, 10, 12, and 12 for MRL/lpr, AMRL/lpr, GMRL/lpr, and AGMRL/lpr, respectively). Furthermore, whereas MRL/lpr animals demonstrated 40% mortality by 24 wk of age, AMRL/lpr animals demonstrated 80%, GMRL/lpr animals demonstrated 0%, and AGMRL/lpr animals demonstrated 25% (n = 10, 10, 12, and 12; p < 0.001 for any comparison between the groups). Thus, type I IFN plays a critical protective role in the development of pathogenic humoral autoimmunity and end organ inflammatory disease.
Role of type I IFN in MRL B cell activation
As such, type I IFNs likely play a suppressive role in B cell activation, at least in MRL mice. However, although autoantibody activities were strongly affected by IFN-RI deficiency (Figs. 3, 5, and 6), total serum Igs were in comparison only modestly affected (Figs. 1 and 2), suggesting a context-specific role and/or importance for type I IFNs in B cell suppression. Because autoantibody activity is critically dependent on T cell help, whereas hypergammaglobulinemia is not, at least in MRL mice (30, 39), type I IFNs might differentially regulate MRL B cell activation during T-dependent vs T-independent Ab responses, as has been found in some prior studies in nonautoimmune strains (12, 25, 44), explaining such observations.
We therefore examined the effect of type I IFN on naive MRL B cells stimulated with LPS, modeling T-independent stimulation, vs anti-CD40, modeling T-dependent stimulation (40), using IFN-A/D, a known murine IFN-RI agonist (11). Remarkably, IFN-A/D significantly inhibited Ig secretion by anti-CD40-stimulated MRL B cells, generally 5- to 10-fold (p < 0.0001; Fig. 7A and our unpublished data). In contrast, it had little, if any, effect on Ig secretion by LPS-simulated cells. Converse results were seen with LPS- vs anti-CD40-stimulated B cells from MRL vs AMRL mice; the latter consistently secreted 3- to 7-fold higher Ig amounts in response to anti-CD40 stimulation (p < 0.001; Fig. 7B and our unpublished data). These results seemed unlikely to represent simply the isolation of more B cells preactivated in vivo from AMRL mice, because our initial B cell isolates were devoid of all IgG class-switch transcripts and unstimulated B cells failed to secrete significant amounts of Ig (Refs. 11 and 40 and data not shown), suggesting that they were indeed naive, non-class-switched cells; nonetheless, we cannot entirely rule out the possibility. Still, these results suggest that type I IFNs can suppress T-dependent humoral immune responses in MRL B cells and furthermore suggest that MRL B cells intrinsically express and/or use type I IFNs to contain and/or limit their overall activity during such responses. As a result, IFN-RI deficiency leads to the exaggerated production of T-dependent autoantibodies, like anti-dsDNA, by autoreactive B cells (Fig. 3 and Refs. 30 and 39).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
T cells (30, 39, 45), and IFN- (13, 14, 15, 16, 18, 19). The present study emphasizes a critical difference between the pathogeneses of at least the NZB, (129 x C57BL/6)-lpr, and MRL models of SLE; the former both apparently rely on both the type I and type II IFNs, although a direct genetic study of both IFNs in those models has not to our knowledge been performed, as done here for MRL. In contrast, in MRL lupus type I IFNs play a critical but protective role, likely by antagonizing the activity of IFN- in the propagation of autoimmune inflammation. Thus, it is likely that different subtypes of human SLE, as they become better codified (46, 47), will reflect different roles for the types I and II IFNs. Similarly, it will be of interest to compare the roles of the type I IFNs in the activation of autoreactive B cells in the various lupus-prone mouse strains. Notably, these conclusions presume that IFNAR1 (CD118) deficiency abrogates all biological activity of type I IFNs in vivo, because it is thought to comprise a critical subunit of the single known type I IFN receptor, IFNAR (48). However, because IFNAR also consists of a second receptor subunit, IFNAR2, and possibly a third as yet undiscovered subunit (48), we cannot rule out the possibility that the remaining IFNAR gene(s) retain some functional ability to recognize type I IFNs with biological consequences below the limit of detection of currently available assays. As a result, some type I IFNs, via the residual IFNAR activity, may in fact exert a pathogenic role in MRL lupus; nonetheless, because by all known in vivo and in vitro assays IFNAR1 deficiency eliminates all biological responses to all type I IFNs tested (e.g., Refs. 32 and 44 and our unpublished data), the present results argue strongly that the predominant role of the type I IFNs is the protection against humoral autoimmunity, at least in the MRL model.
Because type I IFNs can inhibit IFN- expression via STAT1, at least under certain conditions (23), a more plausible mechanism to explain the phenotypes of AMRL and AGMRL animals involves the overexpression of IFN- and/or unopposed STAT1 activity in the absence of IFN-RI. However, cultured lymphocytes from AMRL animals failed to overproduce IFN-, at least compared with MRL counterparts (our unpublished data), and indeed AMRL animals produced serum titers of the IFN-- and STAT1-related isotype IgG2a (49, 50) in levels comparable with those of their IFN-RI+/+ counterparts (Fig. 1). Still, overactivation of at least some critical aspects of the IFN- pathway were responsible, because the more severe end organ disease seen in AMRL/lpr animals was at least partially abrogated in AGMRL/lpr animals (Figs. 4–6 and Table II). Therefore, the IFN pathways responsible for disease pathogenesis could actually be IFN--dependent yet STAT1-independent (51, 52), and a further understanding of the relationship between the types I and II IFNs and their STAT1-dependent and -independent functions will likely shed substantial light on the molecular pathogenesis of SLE.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
1 This work was supported in part by the Siteman Cancer, Rheumatic Diseases, Diabetes Research and Training, and the Digestive Diseases Research Core Centers of the Washington University School of Medicine, as well as grants from the National Institutes of Health (AI01803 and AI057471) and the Lupus Research Institute. S.L.P. is supported in part by an Arthritis Investigator Award from the Arthritis Foundation. 
2 Address correspondence and reprint requests to Dr. Stanford L. Peng, Washington University School of Medicine, Campus Box 8045, CSRB 6617, 660 S. Euclid Avenue, St. Louis, MO 63110. E-mail address: speng{at}wustl.edu
3 Abbreviations used in this paper: SLE, systemic lupus erythematosus; NZB, New Zealand Black; AMRL/+, IFN-RI–/– MRL/+; GMRL/+, IFN-RII–/– MRL/+; AGMRL/+, IFN-RI–/– IFN-RII –/– MRL/+; IFN-RI, IFN receptor type I; IFN-RII, IFN receptor type II; MRL/+, MRL/MpJ-CD95+/+; MRL/lpr, MRL/MpJ-CD95lpr/lpr; IFN-A/D, universal type I IFN; RF, rheumatoid factor.
Received for publication February 9, 2004. Accepted for publication May 21, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
in systemic lupus erythematosus. Science 294:1540. and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944. stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J. Immunol. 140:2121.[Abstract]
of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174:1179. and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936.[Medline]
is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101:364.[Medline]
is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158:5484.[Abstract]
receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 161:494. on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur. J. Immunol. 30:438.[Medline]
R/Fc. J. Clin. Invest. 106:207.[Medline]
is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 60:2173.[Medline]
increases the frequency of interferon -producing human CD4+ T cells. J. Exp. Med. 178:1655./-mediated inhibition and promotion of interferon : STAT1 resolves a paradox. Nat. Immunol. 1:70.[Medline]
. Annu. Rev. Immunol. 15:749.[Medline]
and as immune regulators: a new look. Immunity 14:661.[Medline]
in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. USA 98:15137. T cells. J. Immunol. 156:4041.[Abstract]
receptor. Science 259:1742.
T cells. J. Immunol. 157:5689.[Abstract]
B repressor Foxj1. Science 303:1017./ and interferon receptors. J. Virol. 69:4792.[Abstract]
/ enhances BCR-dependent B cell responses. Int. Immunol. 14:411.+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. J. Immunol. 167:2354.. Proc. Natl. Acad. Sci. USA 98:6674.This article has been cited by other articles:
|
|
 |
|
  T. Kobayashi, K. Takahashi, Y. Nagai, T. Shibata, M. Otani, S. Izui, S. Akira, Y. Gotoh, H. Kiyono, and K. Miyake Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice Int. Immunol., July 1, 2008; 20(7): 881 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atkinson, F. Qiao, H. Song, G. S. Gilkeson, and S. Tomlinson Low-Dose Targeted Complement Inhibition Protects against Renal Disease and Other Manifestations of Autoimmune Disease in MRL/lpr Mice J. Immunol., January 15, 2008; 180(2): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asokan, J. Hua, K. A. Young, H. J. Gould, J. P. Hannan, D. M. Kraus, G. Szakonyi, G. J. Grundy, X. S. Chen, M. K. Crow, et al. Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN-{alpha}: A Potential Role in Systemic Lupus Erythematosus J. Immunol., July 1, 2006; 177(1): 383 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Savarese, O.-w. Chae, S. Trowitzsch, G. Weber, B. Kastner, S. Akira, H. Wagner, R. M. Schmid, S. Bauer, and A. Krug U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7 Blood, April 15, 2006; 107(8): 3229 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Srivatsan and S. L. Peng Cutting Edge: Foxj1 Protects against Autoimmunity and Inhibits Thymocyte Egress J. Immunol., December 15, 2005; 175(12): 7805 - 7809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Kitching More Targeted Treatments for Lupus Nephritis: Is the Future (Nearly) Here? J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3146 - 3148. [Full Text] [PDF]
|
|
|
|
|
|
A. Schwarting, K. Paul, S. Tschirner, J. Menke, T. Hansen, W. Brenner, V. R. Kelley, M. Relle, and P. R. Galle Interferon-{beta}: A Therapeutic for Autoimmune Lupus in MRL-Faslpr Mice J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3264 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Christensen, M. Kashgarian, L. Alexopoulou, R. A. Flavell, S. Akira, and M. J. Shlomchik Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus J. Exp. Med., July 18, 2005; 202(2): 321 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Subramanian, Y.-S. Yim, K. Liu, K. Tus, X. J. Zhou, and E. K. Wakeland Epistatic Suppression of Systemic Lupus Erythematosus: Fine Mapping of Sles1 to Less Than 1 Mb J. Immunol., July 15, 2005; 175(2): 1062 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mathian, A. Weinberg, M. Gallegos, J. Banchereau, and S. Koutouzov IFN-{alpha} Induces Early Lethal Lupus in Preautoimmune (New Zealand Black x New Zealand White)F1 but Not in BALB/c Mice J. Immunol., March 1, 2005; 174(5): 2499 - 2506. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||
